[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 62, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 885600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 677758, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 402304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 45625, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sheng  Cui Ph.D.", "title": "Chief Manufacturing Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 21.1, "open": 20.98, "dayLow": 20.0, "dayHigh": 21.1799, "regularMarketPreviousClose": 21.1, "regularMarketOpen": 20.98, "regularMarketDayLow": 20.0, "regularMarketDayHigh": 21.1799, "beta": -0.001, "forwardPE": -11.5872, "volume": 298590, "regularMarketVolume": 298590, "averageVolume": 927970, "averageVolume10days": 753890, "averageDailyVolume10Day": 753890, "bid": 20.07, "ask": 20.21, "bidSize": 200, "askSize": 200, "marketCap": 2161400064, "fiftyTwoWeekLow": 15.19, "fiftyTwoWeekHigh": 27.29, "priceToSalesTrailing12Months": 64.338875, "fiftyDayAverage": 23.223, "twoHundredDayAverage": 19.941925, "currency": "USD", "enterpriseValue": 1443047808, "floatShares": 36261455, "sharesOutstanding": 107053000, "sharesShort": 2991295, "sharesShortPriorMonth": 2584311, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.0279, "heldPercentInsiders": 0.00408, "heldPercentInstitutions": 0.8797, "shortRatio": 4.69, "shortPercentOfFloat": 0.042600002, "impliedSharesOutstanding": 107053000, "bookValue": 4.111, "priceToBook": 4.911214, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -198916000, "trailingEps": -2.21, "forwardEps": -1.89, "enterpriseToRevenue": 42.956, "enterpriseToEbitda": -7.84, "52WeekChange": -0.027924895, "SandP52WeekChange": 0.19995654, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "NAMS", "underlyingSymbol": "NAMS", "shortName": "NewAmsterdam Pharma Company N.V", "longName": "NewAmsterdam Pharma Company N.V.", "firstTradeDateEpochUtc": 1612881000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "eaa26311-e3c9-331e-9693-8ad0dbaf89e6", "messageBoardId": "finmb_685404834", "gmtOffSetMilliseconds": -18000000, "currentPrice": 20.19, "targetHighPrice": 52.101837, "targetLowPrice": 35.134266, "targetMeanPrice": 44.00571, "targetMedianPrice": 45.221027, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 422728992, "totalCashPerShare": 4.576, "ebitda": -184059008, "totalDebt": 506000, "quickRatio": 10.371, "currentRatio": 10.614, "totalRevenue": 33594000, "debtToEquity": 0.134, "revenuePerShare": 0.373, "returnOnAssets": -0.29273, "returnOnEquity": -0.47369, "grossProfits": 33594000, "freeCashflow": -108734752, "operatingCashflow": -154156992, "revenueGrowth": 8.898, "grossMargins": 1.0, "operatingMargins": -0.85888, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]